News
CANF
3.250
-6.61%
-0.230
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
TipRanks · 2d ago
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
TipRanks · 2d ago
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis
Benzinga · 2d ago
CAN-FITE ACHIEVES KEY PIVOTAL PHASE 3 PSORIASIS MILESTONE WITH COMPLETION OF PATIENT ENROLMENT FOR THE INTERIM ANALYSIS: DATA EXPECTED Q4 2026/Q1 2027
Reuters · 2d ago
Weekly Report: what happened at CANF last week (0629-0703)?
Weekly Report · 2d ago
11 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 6d ago
Can-Fite Biopharma Price Target Raised to $8.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8
Benzinga · 6d ago
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
TipRanks · 6d ago
Biggest stock movers Thursday: FIZZ, CANF, and more
Seeking Alpha · 6d ago
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch
NASDAQ · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/01 17:05
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
Benzinga · 07/01 14:13
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/01 12:05
Can-Fite's Namodenoson Shows Survival Benefits In Pancreatic Cancer; Stock Jumps Pre-Market
NASDAQ · 07/01 11:57
Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial
TipRanks · 07/01 11:27
Market-Moving News for July 1st
Benzinga · 07/01 11:16
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
TipRanks · 07/01 11:05
Weekly Report: what happened at CANF last week (0622-0626)?
Weekly Report · 06/29 09:37
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/26 21:05
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.